إعلان مُمول
Bharat Biotech in-licences GSK's Shigella vaccine candidate
نشر بتاريخ
Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early-stage trials by GSK, Bharat Biotech will advance the vaccine through Phase-III trials, regulatory processes, and large-scale production. This collaboration strengthens Bharat Biotech's portfolio of vaccines against diarrheal infections.
البحث
الأقسام
- National
- International
- Business
- Technology
- Health
- التعليم
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
إقرأ المزيد
RBI finalises co-lending framework starting Jan 2026
RBI's final co-lending rules, effective January 1, 2026, introduce blended lending rates and...
Use crisis to unleash reforms: Mahindra
Anand Mahindra believes US tariffs will inadvertently foster new growth opportunities. He...